menu
    • menu
    [{"orgOrder":0,"company":"Creyon Bio","sponsor":"DCVC Bio","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Discovery Platform","graph3":"Creyon Bio","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Creyon Bio \/ DCVC Bio","highestDevelopmentStatusID":"3","companyTruncated":"Creyon Bio \/ DCVC Bio"},{"orgOrder":0,"company":"Creyon Bio","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Oligonucleotide","year":"2025","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Discovery Platform","graph3":"Creyon Bio","amount2":1.01,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Rare Diseases","amount2New":1.01,"dosageForm":"Undisclosed","sponsorNew":"Creyon Bio \/ Eli Lilly","highestDevelopmentStatusID":"3","companyTruncated":"Creyon Bio \/ Eli Lilly"}]

    Find Rare Diseases and Disorders Clinical Drug Pipeline Developments & Deals by Creyon Bio

    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Creyon Bio

                            U.S.A arrow
                            Breast Cancer
                            Not Confirmed

                            Creyon Bio

                            U.S.A arrow
                            Breast Cancer
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Rare Diseases and Disorders

                            Study Phase : Discovery Platform

                            Sponsor : Eli Lilly

                            Deal Size : $1,013.0 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Creyon Bio and Lilly Enter into RNA-Targeted Oligo Therapy Development Collaboration

                            Details : Through the collaboration, Creyon will leverage its industry-first AI-Powered Oligo Engineering Engine to design and optimize new drug candidates for Lilly’s named targets.

                            Product Name : Undisclosed

                            Product Type : Oligonucleotide

                            Upfront Cash : $13.0 million

                            April 29, 2025

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Rare Diseases and Disorders

                            Highest Development Status : Discovery Platform

                            Sponsor : Eli Lilly

                            Deal Size : $1,013.0 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Creyon Bio

                            U.S.A arrow
                            Excipient World
                            Not Confirmed

                            Creyon Bio

                            U.S.A arrow
                            Excipient World
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Rare Diseases and Disorders

                            Study Phase : Discovery

                            Sponsor : DCVC Bio

                            Deal Size : $40.0 million

                            Deal Type : Series A Financing

                            DEALS_DEV arrow-down

                            Creyon Bio Launches to Engineer Safe, Effective Precision Medicines on Demand for All Patients

                            Details : The proceeds of financing will support continued optimization of the Creyon Platform, expanding the team, and laying the foundations for a diverse internal pipeline. Creyon’s drug development platform creates purpose-built data sets orders of efficient...

                            Product Name : Undisclosed

                            Product Type : Oligonucleotide

                            Upfront Cash : Undisclosed

                            August 03, 2022

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Rare Diseases and Disorders

                            Highest Development Status : Discovery

                            Sponsor : DCVC Bio

                            Deal Size : $40.0 million

                            Deal Type : Series A Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth